Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Inducible Loss of the Aryl Hydrocarbon Receptor Activates Perigonadal White Fat Respiration and Brown Fat Thermogenesis via Fibroblast Growth Factor 21.

Authors: Girer, Nathaniel G; Carter, Dwayne; Bhattarai, Nisha; Mustafa, Mehnaz; Denner, Larry; Porter, Craig; Elferink, Cornelis J

Published In Int J Mol Sci, (2019 Feb 22)

Abstract: The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor highly expressed in hepatocytes. Researchers have employed global and liver-specific conditional Ahr knockout mouse models to characterize the physiological roles of the AHR; however, the gestational timing of AHR loss in these models can complicate efforts to distinguish the direct and indirect effects of post-gestational AHR deficiency. Utilizing a novel tamoxifen-inducible AHR knockout mouse model, we analyzed the effects of hepatocyte-targeted AHR loss in adult mice. The data demonstrate that AHR deficiency significantly reduces weight gain and adiposity, and increases multilocular lipid droplet formation within perigonadal white adipose tissue (gWAT). Protein and mRNA expression of fibroblast growth factor 21 (FGF21), an important hepatokine that activates thermogenesis in brown adipose tissue (BAT) and gWAT, significantly increases upon AHR loss and correlates with a significant increase of BAT and gWAT respiratory capacity. Confirming the role of FGF21 in mediating these effects, this phenotype is reversed in mice concomitantly lacking AHR and FGF21 expression. Chromatin immunoprecipitation analyses suggest that the AHR may constitutively suppress Fgf21 transcription through binding to a newly identified xenobiotic response element within the Fgf21 promoter. The data demonstrate an important AHR-FGF21 regulatory axis that influences adipose biology and may represent a "druggable" therapeutic target for obesity and its related metabolic disorders.

PubMed ID: 30813227 Exiting the NIEHS site

MeSH Terms: Adipose Tissue, Brown/metabolism*; Adipose Tissue, White/drug effects; Adipose Tissue, White/metabolism*; Adiposity/drug effects; Animals; Body Weight/drug effects; Cell Respiration*/drug effects; Diet, High-Fat; Drinking; Energy Metabolism/drug effects; Feeding Behavior/drug effects; Female; Fibroblast Growth Factors/genetics; Fibroblast Growth Factors/metabolism*; Gonads/drug effects; Gonads/metabolism*; Hepatocytes/drug effects; Hepatocytes/metabolism; Lipid Droplets/metabolism; Liver/drug effects; Liver/metabolism; Mice; Mice, Knockout; Phenotype; Physical Conditioning, Animal; Promoter Regions, Genetic/genetics; Protein Binding/drug effects; Receptors, Aryl Hydrocarbon/metabolism*; Tamoxifen/pharmacology; Thermogenesis*/drug effects; Transcription, Genetic/drug effects

to Top